4.5 Article

White matter hyperintensities are associated with grey matter atrophy and cognitive decline in Alzheimer's disease and frontotemporal dementia

期刊

NEUROBIOLOGY OF AGING
卷 111, 期 -, 页码 54-63

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2021.11.007

关键词

White matter hyperintensities; small-vessel disease; neurodegenerative disease; Alzheimer's disease; fronto-temporal dementia; Parkinson's disease; mild cognitive impairment

资金

  1. Famille Louise AndreCharron
  2. Canadian Consortium on Neurodegeneration in Aging
  3. Alzheimer Society Research Program (ASRP) postdoctoral award
  4. Canadian Institutes of Health Research
  5. Alzheimer Society of Canada
  6. Sanofi
  7. Women's Brain Health Initiative
  8. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  9. DOD ADNI (Department of Defense) [W81XWH-12-20012]
  10. National Institute on Aging
  11. National Institute of Biomedical Imaging and Bioengineering
  12. AbbVie
  13. Alzheimer's Association
  14. Alzheimer's Drug Discovery Foundation
  15. Araclon Biotech
  16. BioClinica, Inc.
  17. Biogen
  18. Bristol-Myers Squibb Company
  19. CereSpir, Inc.
  20. Cogstate
  21. Eisai Inc.
  22. Elan Pharmaceuticals, Inc.
  23. Eli Lilly and Company
  24. EuroImmun
  25. F. Hoffmann-La Roche Ltd.
  26. Genentech, Inc.
  27. Fujirebio
  28. GE Healthcare
  29. IXICO Ltd.
  30. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  31. Johnson & Johnson Pharmaceutical Research & Development LLC.
  32. NeuroRx Research
  33. Novartis Pharmaceuticals Corporation
  34. Pfizer Inc.
  35. Piramal Imaging
  36. Servier
  37. Takeda Pharmaceutical Company
  38. Transition Therapeutics
  39. Michael J Fox Foundation for Parkinson's Research
  40. Avid Radiopharmaceuticals
  41. Bristol-Myers Squibb
  42. Covance
  43. Genentech
  44. GlaxoSmithKline (GSK)
  45. Lundbeck
  46. Merck
  47. Meso Scale Discovery (MSD)
  48. Pfizer
  49. Roche
  50. UCB
  51. Lumosity
  52. Merck Co., Inc.
  53. Meso Scale Diagnostics, LLC.
  54. Neurotrack Technologies
  55. Frontotemporal Lobar Degeneration Neuroimaging Initiative (National Institutes of Health Grant) [R01 AG032306]

向作者/读者索取更多资源

White matter hyperintensities may have a synergistic effect in the neurodegenerative processes of mild cognitive impairment, Alzheimer's dementia, and fronto-temporal dementia, affecting grey matter atrophy and cognition.
White matter hyperintensities (WMHs) are commonly assumed to represent non-specific cerebrovascular disease comorbid to neurodegenerative processes, rather than playing a synergistic role. We compared the impact of WMHs on grey matter (GM) atrophy and cognition in normal aging (n = 571), mild cognitive impairment (MCI, n = 551), Alzheimer's dementia (AD, n = 212), fronto-temporal dementia (FTD, n = 125), and Parkinson's disease (PD, n = 271). Longitudinal data were obtained from ADNI, FTLDNI, and PPMI datasets. Mixed-effects models were used to compare WMHs and GM atrophy between patients and controls and assess the impact of WMHs on GM atrophy and cognition. MCI, AD, and FTD patients had significantly higher WMH loads than controls. WMHs were related to GM atrophy in insular and parieto-occipital regions in MCI/AD, and frontal regions and basal ganglia in FTD. In addition, WMHs contributed to more severe cognitive deficits in AD and FTD compared to controls, whereas their impact in MCI and PD was not significantly different from controls. These results suggest potential synergistic effects between WMHs and proteinopathies in the neurodegenerative process in MCI, AD and FTD. (C) 2021 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据